Understanding the rapidly changing landscape of GLP-1 medications is key for employers who are looking to control rising Rx costs. 

Our data shows that the bottom 25% of doctors have a waste rate 6x higher than the top 25%.

These low value prescriptions have a big impact on GLP-1 outcomes and ultimately cost.

In this discussion between Garner CEO, Nick Reber, and Chief Research and Data Science Officer, Phil Salinger, you’ll discover the significant impact of GLP-1s on employer health plans, and strategies to address these challenges.